Melanoma
Todd M. Blodgett, MD
Alex Ryan, MD
Omar Almusa, MD
Key Facts
Terminology
-
Malignant melanoma (MM)
Imaging Findings
-
CT
-
CECT is better than FDG PET for detection of small pulmonary metastases
-
Less sensitive than FDG PET for bone, skin, lymph node, abdominal metastases
-
Combination of FDG PET and conventional imaging (CT/MR) more accurate than either one alone
-
CT generally performed for staging and restaging purposes
-
-
PET/CT
-
Detects more lesions than CT, particularly intramuscular and other unsuspected metastases
-
More exact method of determining FDG uptake in a mass
-
Staging: Sensitivity 83%, specificity 91%
-
Restaging: 74% sensitivity 74%, specificity 86% for recurrence
-
-
In one study, 16% of patients underwent further imaging &/or biopsies that ultimately had no effect on patient care
Top Differential Diagnoses
-
Other Neoplasms
-
Inflammation/Infection
-
Brown Fat
Clinical Issues
-
Tumor thickness = most important histologic prognostic indicator
TERMINOLOGY
Abbreviations and Synonyms
-
Malignant melanoma (MM)
-
Skin cancer
Definitions
-
Melanoma: Neoplasm of melanin-producing cells
IMAGING FINDINGS
General Features
-
Best diagnostic clue: FDG-avid focal uptake on PET seen in primary, satellite lesions, lymph nodes (LN), visceral organs, and bone
-
Location
-
Primary melanoma
-
Men: Torso most common
-
Women: Upper extremities most common
-
4-5% of primary melanoma may arise in extracutaneous location
-
Locations include eye, meninges, mucous membranes of digestive, genitourinary, respiratory tracts
-
Multiple primaries occur in ˜ 5% of patients
-
-
Local spread
-
At or near previous excision site
-
Recent biopsy or other inflammation may produce false positive on FDG PET
-
Sentinal node tumor may alter stage
-
-
Metastatic disease
-
In-transit nodal metastases: Between primary and regional lymph nodes
-
Regional lymph nodes
-
Common sites: Spine, brain, lung, liver, spleen, bowel
-
Clinically apparent brain metastases found in 18-46% of patients with stage IV disease
-
Conjunctival melanoma may present with systemic metastases in 26% of cases without regional lymph node involvement
-
-
-
Size
-
Size considerations usually relative to depth of lesion
-
Stage is dependent on depth
-
-
Morphology: Malignant lymph nodes are typically round with absence of fatty hilum
Imaging Recommendations
-
Best imaging tool
-
FDG PET
-
May reveal focal increased uptake in lymph node bed, soft tissue, and organs
-
More sensitive than CT for skin, LN, bone, and abdominal metastases
-
-
CECT
-
Exclusion of benign structures with FDG uptake
-
Accurate delineation of primary and metastatic tumor in lymph node bed, soft tissue, and organs
-
Superior detection of small pulmonary metastases
-
Inclusion of lymph nodes by size or morphology (round without fatty hilum)
-
-
MR
-
For definition of brain metastases
-
-
-
Protocol advice
-
FDG PET
-
Evaluate skin for lesions with non-attenuation corrected PET images
-
Attenuation correction can smooth data, obscuring lesions
-
PET scan often extended to true whole-body coverage due to metastatic behavior of melanoma
-
Clinical history crucial: False positives with recent surgery, biopsy, inflammation
-
-
Total lesion glycolysis (TLG) approach
-
More exact method of determining FDG uptake in a mass
-
Has failed to show superiority over simpler SUV measurement
-
-
Longer FDG uptake times may correlate to better overall sensitivity/specificity
-
In general, more uptake in malignant lesions and less uptake in benign lesions is seen at 2 or 3 hour time point
-
-
CT Findings
-
CT generally performed for staging and restaging purposes
-
Not used to evaluate primary lesions
-
-
NECT: Less sensitive for detecting metastatic lesions than CECT
-
CECT: More sensitive for evaluation of organs and non-nodal soft tissue such as muscle
-
General
-
After typical search pattern, look again at muscle, gallbladder, and other subcutaneous soft tissues
-
-
Brain
-
Imaging performed for patients with known metastatic disease
-
Also performed for patients with neurological symptoms in the absence of known metastases
-
MR with contrast much more sensitive for detecting small brain metastases
-
-
Chest
-
May detect asymptomatic lesions
-
NECT and CECT approximately equal for detecting small pulmonary metastases
-
FDG PET less sensitive in general for detecting lung metastases ≤ 6 mm
-
-
Abdomen
-
Organ metastases may show hyperenhancement
-
Intramuscular metastases will generally show some abnormal enhancement, but may be otherwise undetectable
-
-
Pelvis
-
More likely positive in patients with primary disease below waist
-
-
Bone
-
Some may demonstrate enhancement, making them more conspicuous
-
Extensive bone metastasis may be missed altogether
-
-
Nuclear Medicine Findings
-
General
-
Melanoma is almost always FDG avid
-
True positives have significantly higher SUV than false positives in lesions > 1 cm on PET/CT
-
PET/CT has considerable but non-significant advantage over PET in characterization of lesions
-
Possibly due to high avidity of melanoma metastases
-
Certainty of lesion localization significantly improved with combined modality
-
Especially in detection of visceral metastases
-
-
Accuracy of PET/CT higher when equivocal lesions are considered negative
-
PET/CT recommended for stage III/IV patients
-
Thorough physical exam and US of draining nodes for lower stage patients
-
PET/CT may detect unheralded occult primary malignancy in patients with primary melanoma
-
Choroidal melanoma reported to have low FDG uptake
-
Correlated strongly to lesion size
-
-
Intra-operative FDG PET/CT
-
Handheld gamma probe used to find lesions during surgery
-
Used to verify intra-operative US findings
-
Used to verify excised tissue as being the FDG-avid lesion
-
Can evaluate residual sites of hypermetabolic activity immediately post-operatively
-
-
-
Staging
-
PET established as useful modality for staging and restaging of cutaneous melanoma and for evaluating distant metastases
-
Large meta-analysis: Sensitivity 83% and specificity 91% for staging
-
Changes management in 26-50% of patients
-
In one study, 16% of patients underwent further imaging &/or biopsies that ultimately had no effect on patient care
-
-
Local or early disease
-
PET/CT found to have high accuracy for evaluation of regional metastases
-
Sensitivity 23% if metastases ≤ 5 mm (e.g., small lung nodules)
-
One study concluded that PET reliably detects lymph node tumor deposits > 80 mm3
-
Loses sensitivity rapidly below that volume
-
Not reimbursable by Medicare for evaluation of regional lymph nodes in stage I/II disease
-
More sensitive in setting of clinical or radiographic evidence of disease
-
-
Distant disease
-
Sensitivity ≥ 90% for lesions > 1 cm
-
Reimbursable by Medicare for evaluation of extranodal metastases during initial staging
-
Sensitivity of 60% with FDG PET for brain metastases due to high physiologic uptake in the brain
-
Organ-based accuracy in liver, lung, and brain variable
-
Accuracy of PET/CT for M-staging higher than that of PET or CT alone (98%, 93%, 84%, respectively)
-
Superior sensitivity for lung metastases compared to MR
-
-
PET/CT of node positive melanoma at time of sentinal lymphadenectomy had management change in 31% of one patient cohort
-
CT/MR in this circumstance shown to yield less than 1%; not clinically indicated
-
Level of uptake in lymph node metastases correlates with recurrence risk
-
-
-
Restaging
-
FDG PET detects recurrent disease with sensitivity/specificity 74%/86%
-
Elevated laboratory markers or clinical evidence of recurrence should prompt re-imaging
-
Pre-surgical evaluation may detect more extensive disease and alter surgical planning
-
FDG PET reimbursed by Medicare for pre-surgical evaluation of recurrence
-
-
Response to therapy
-
PET/CT not routinely performed
-
Likely will play a more significant role in evaluating patients after various immunomodulating therapies
-
-
One study showed complete agreement differentiating chemo-responders and nonresponders between CT and PET/CT
-
Baseline FDG PET very helpful for evaluating response to therapy
-
Melanoma differs from malignancies such as lymphoma, in which metabolic changes precede morphologic changes
-
PET/CT has benefit of relative ease of interpretation, but some controversy exists as to cost/benefit ratio
-
FDG PET pitfall: Cytokine therapy results in diffuse hypermetabolism in normal lymph nodes for months
-
-
MR Findings
-
More accurate in detection of mets to liver and bone
-
Hepatic metastases ≤ 1 cm and containing melanin have bright signal on T1 weighted MR
-
DIFFERENTIAL DIAGNOSIS
Other Neoplasms
-
May appear similar to melanoma in FDG avidity
-
If suspicion of melanoma recurrence is low, consider
-
Primary or metastatic disease from second primary
-
Unheralded second primary malignancies detected in 1.2% of patients (lung most common)
-
-
Squamous or basal cell carcinoma
-
Lymphoma in the presence of lymphadenopathy
-
Reactive Lymph Nodes
-
Look for CT evidence of other causes of reactive lymphadenopathy, e.g., colitis, pancreatitis, pneumonia
Inflammation/Infection
-
Pneumonia
-
May present with focal FDG uptake that mimics hypermetabolic nodule
-
CT correlation and follow-up studies are helpful to avoid unnecessary biopsy
-
-
Granulomatous infection may manifest as enlarged, hypermetabolic lymph nodes
-
Mycobacterium avium intracellulare
-
Tuberculosis
-
Sarcoidosis
-
Histoplasmosis
Stay updated, free articles. Join our Telegram channel
-

Full access? Get Clinical Tree

